The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 290.00
Bid: 285.00
Ask: 289.00
Change: 0.00 (0.00%)
Spread: 4.00 (1.404%)
Open: 290.00
High: 0.00
Low: 0.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

2 Jul 2021 09:30

RNS Number : 9844D
Hutchmed (China) Limited
02 July 2021
 

HUTCHMED to Announce 2021 Half-Year Financial Results

 

Hong Kong, Shanghai & Florham Park, NJ - Friday, July 2, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2021 on Wednesday, July 28, 2021 at 12:00 noon British Summer Time (BST) (7:00 pm Hong Kong Time (HKT); 7:00 am Eastern Daylight Time (EDT)).

 

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

 

The conference call and audio webcast will take place at 1:00 pm BST / 8:00 pm HKT / 8:00 am EDT on Wednesday, July 28, 2021 and will be webcast live via the company website at www.hutch-med.com/investors/event-information/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM; SEHK: 13) (formerly Hutchison China MediTech) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

 

 

CONTACTS

 

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)HUTCHMED@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile) / +852 9783 6894 (Mobile)

HUTCHMED@brunswickgroup.com

Nominated Advisor

Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORQLLBBFDLFBBB
Date   Source Headline
18th Jun 20077:00 amRNSR&D Facility Purchase
23rd May 20077:00 amRNSResearch Update
22nd May 20077:00 amRNSDirector/PDMR Shareholding
11th May 20073:57 pmRNSResult of AGM
12th Apr 20077:00 amRNSNotice of AGM
2nd Apr 20077:04 amRNSBoard Change
23rd Mar 20077:00 amRNSDirector/PDMR Shareholding
21st Mar 200712:10 pmRNSFinal Results
26th Feb 20077:00 amRNSNotice of Results
17th Jan 20077:00 amRNSRelated Party Transaction
5th Jan 20077:53 amRNSAppointment of Joint Broker
20th Nov 20067:02 amRNSCollaboration Agreement
6th Nov 20067:01 amRNSDevelopment Agreement
29th Sep 20067:00 amRNSSenior Board Appointment
9th Aug 20067:21 amRNSInterim Results
26th Jul 200610:00 amRNSNotice of Results
17th Jul 20067:00 amRNSTrading Update
4th Jul 20067:00 amRNSClinical Update
19th May 200610:47 amRNSDirector/PDMR Shareholding
19th May 20067:01 amRNSFirst Day Trading

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.